Feasibility of bevacizumab (BEV) plus chemotherapy in heavily pretreated ovarian cancer (OC) patients (pts): A retrospective study. Background: Rising serum cancer antigen 125 (CA-125) trends within ...

Efficacy of pegylated liposomal doxorubicin (PLD) and oxaliplatin (Ox) in pre-treated advanced epithelial ovarian cancer (EOC) in relation to BRCA status No significant financial relationships to ...

Recurrent epithelial ovarian carcinoma is considered an incurable disease, and second-line chemotherapy is mainly considered for palliation of symptoms and extension of survival. There are a growing ...

Current treatment guidelines recommend using cancer antigen-125 (CA-125) as a diagnostic marker for ovarian cancer recurrence, but a recent study suggests CA-125 has poor concordance with progressive ...

Current CA-125 thresholds may miss ovarian cancer in racially diverse patients, delaying treatment initiation and contributing to health disparities. Original CA-125 studies were conducted on ...